Intuitive Surgical (ISRG) Stock Could Be Undervalued On Cash Flow But Overvalued On Earnings
Intuitive Surgical stock has dropped about 34.3% year to date, yet the Discounted Cash Flow (DCF) intrinsic value estimate points to the shares trading at roughly a 10.2% discount, while traditional market multiples still flag the company as expensive. That split leaves investors weighing a pessimistic recent share price path against valuation tools that point in very different directions.
- The year to date decline of 34.3% suggests sentiment around Intuitive Surgical has weakened sharply, even as the underlying business remains central to robotic surgery.
- Fresh clinical data supporting improved outcomes with da Vinci procedures can underpin long term cash flow expectations, while heavier R&D spending and rising competition may pressure profitability and keep some investors cautious.
- On a broad set of checks, Intuitive Surgical leans expensive. The company screens as undervalued in only 1 of 6 valuation metrics, even though the DCF view indicates some upside to intrinsic value.
The issue now is whether the DCF style intrinsic value case or the richer market multiple profile ends up being the better guide for where Intuitive Surgical stock should trade.
Capitalize on the reset in Intuitive Surgical by scanning a curated list of 38 robotics and automation stocks that could be setting up for the next leg of adoption in surgical and automation technology.Does Intuitive Surgical Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach estimates what Intuitive Surgical is worth based on the cash it can generate for shareholders over time. On this model, the business is treated as a growing cash generator, with latest twelve month free cash flow of about $2.7b feeding into long run projections. That stream of projected cash flows translates into an estimated intrinsic value of around $411 per share in $ terms.
With the current share price sitting about 10.2% below that DCF estimate, Intuitive Surgical screens as undervalued on a pure cash flow lens. The recent meta analysis showing better patient outcomes for da Vinci procedures gives some investors more confidence in those long term cash flow assumptions, because it indicates staying power in robotic surgery usage rather than a passing technology trend.
On this DCF view, Intuitive Surgical stock appears undervalued relative to what its projected cash flows suggest it could be worth.
Our Discounted Cash Flow (DCF) analysis suggests Intuitive Surgical is undervalued by 10.2%. Track this in your watchlist or portfolio, or discover 31 more high quality undervalued stocks.
Does Intuitive Surgical Look Pricey on Earnings?
P/E fits Intuitive Surgical well because earnings have become a central reference point for how investors judge the robotic surgery leader against medical equipment peers.
Through this lens, the stock trades on a P/E of about 41.5x, compared with an industry average of roughly 24.5x and a peer group closer to 25.1x. A fair P/E for Intuitive Surgical, based on its profile relative to the sector, is estimated at about 35.3x, which remains below where the shares currently change hands.
That gap means the valuation screens as rich even after adjusting for the company’s size, margins, and risk profile. The recent meta analysis pointing to better outcomes for da Vinci surgery can help explain why some investors are willing to pay a higher price, but the numbers still show a clear premium to what the model highlights as a more grounded earnings multiple.
On the P/E check, Intuitive Surgical stock appears overvalued relative to both its tailored fair ratio and the wider medical equipment group.
See what the numbers say about this price — find out in our valuation breakdown.
The Intuitive Surgical Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this Intuitive Surgical valuation gap leaves off by spelling out which combinations of growth, profitability and earnings power would need to play out for the stock to be worth meaningfully more or less than today’s price on the Community page. Rather than leaning on a single ratio or model, each narrative lays out the assumptions that sit behind its view of fair value so you can weigh those against actual results as they arrive.
Community views on Intuitive Surgical are miles apart, with some holders calling it close to fair value while others argue expectations still look stretched.
Bull case: 31% undervalued
"ISRG’s robust business model and strong moat come from this recurring revenue, as hospitals must continuously purchase instruments, maintenance services, and software updates to keep their da Vinci systems operational…"
Read the full Bull Case to see why Intuitive Surgical could be undervalued
Bear case: 14% overvalued
"Intensifying global healthcare cost pressures and expanding government regulation are expected to force more aggressive pricing controls and reimbursement scrutiny in key markets, which would severely limit Intuitive Surgical's ability to sustain current average selling prices and curtail both revenue and net margin expansion over time…"
Read the full Bear Case to see why Intuitive Surgical could be overvalued
Do you think there's more to the story for Intuitive Surgical? Head over to our Community to see what others are saying!
The Bottom Line
Intuitive Surgical presents a clean split. The Discounted Cash Flow (DCF) view points to some intrinsic value upside, while the market multiple work still flags the shares as overvalued relative to peers and a tailored fair P/E. That clash comes from different sensitivities, with the intrinsic model leaning on long run cash generation and capital needs, and the multiples leaning on how much future growth investors are already pricing in. The key question from here is whether Intuitive Surgical can deliver the procedure volumes and margins implied in the DCF without the P/E having to compress further.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com